Alamar Biosciences, Inc. (Ticker: ALMR US) is an American company specializing in precision proteomics and advanced protein detection and analysis. Alamar Biosciences plans to list on the NASDAQ on April 17, 2026, planning to offer 9,375,000 primary shares at a price range of $15.00 to $17.00, raising approximately $150 million. According to sources, Alamar Biosciences plans to use the IPO proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures.

Reportedly, the company's proprietary NULISA technology and ARGO HT System enable ultra-high sensitivity and multiplexed biomarker analysis for early disease detection across discovery, translational research, and clinical diagnostics. The commercial-stage company generated total revenue of $74.2 million in 2025, which represents a 195% year-over-year growth. Founded in 2018 and headquartered in Fremont, California, the organization is currently led by Founder, Chairman, and CEO Yuling Luo alongside President Tod White. J.P. Morgan, Bank of America, and TD Cowen are reportedly acting as joint bookrunners for the IPO, with J.P. Morgan also serving as the stabilization agent and handling bill and deliver responsibilities.